The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Vispa-cel, an allogeneic CAR-T, in patients with R/R B-cell NHL: results from ANTLER trial
Stephen Schuster, MD, University of Pennsylvania, Philadelphia, PA, discusses the results of the Phase I ANTLER clinical trial (NCT04637763) investigating vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR T-cell therapy with a PD-1 knockout, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Prof. Schuster believes that this construct holds great potential due to the minimal toxicity and promising efficacy observed in this trial, and he anticipates that the planned randomized trial will demonstrate the superiority of vispa-cel over standard of care. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
